Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
株式のランク #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
株価
$150.78
最終同期: 2026-09-18
時価総額
$187.20B
変化(1日)
-0.08%
変化(1年)
32.15%
US
取引 Gilead Sciences, Inc. (GILD)

カテゴリー

Gilead Sciences, Inc.(GILD)の発行済株式数
June 2026 時点の発行済株式数 1.24B
Gilead Sciences, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 1.24B です。December 2024 の終わりには、同社は 1.25B 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Gilead Sciences, Inc.(GILD)の発行済株式数の履歴(2000 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
2026 (TTM) 1.24B -0.08%
2025 1.24B -0.24%
2024 1.25B -0.08%
2023 1.25B -0.56%
2022 1.26B -0.08%
2021 1.26B -0.08%
2020 1.26B -1.02%
2019 1.27B -2.16%
2018 1.30B -0.69%
2017 1.31B -2.39%
2016 1.34B -8.54%
2015 1.46B -3.81%
2014 1.52B -0.43%
2013 1.53B 0.92%
2012 1.51B -2.27%
2011 1.55B -9.48%
2010 1.71B -5.37%
2009 1.81B -1.75%
2008 1.84B -0.91%
2007 1.86B 1.19%
2006 1.84B 1.05%
2005 1.82B 5.17%
2004 1.73B 7.41%
2003 1.61B 2.84%
2002 1.56B 2.78%
2001 1.52B 4.47%
2000 1.46B 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数
892.40M -28.21%
US
2.44B 96.31%
US
1.77B 42.48%
US
796.00M -35.96%
CH
0.00 -100.00%
US